← All trials
NCT02550106
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2015
- Primary completion
- Jan 1, 2016
- Completion date
- Jan 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 136
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- NovartisLead sponsor
- University of RennesOverall official - principal investigator
- CHI DE CORNOUAILLE - QUIMPER CEDEXOverall official - principal investigator
- CH DE CHALONS EN CHAMPAGNE - CHALONS EN CHAMPAGNE CEDEXOverall official - principal investigator
- CHU EstaingOverall official - principal investigator
- HOPITAL CAREMEAUOverall official - principal investigator
- HOPITAL LARREY - TOULOUSEOverall official - principal investigator
- HOPITAL ST VINCENT DE PAUL - LILLE CEDEXOverall official - principal investigator
- University of ParisOverall official - principal investigator
- University of BordeauxOverall official - principal investigator
- Aix-University of MarseilleOverall official - principal investigator
- University of MontpellierOverall official - principal investigator
- University of LorraineOverall official - principal investigator
- Rouen Normandy UniversityOverall official - principal investigator
- Hospital AvicenneOverall official - principal investigator
- University of LyonOverall official - principal investigator
- CHR LA MILETRIEOverall official - principal investigator
- CHU Henri MondorOverall official - principal investigator
- CH VICTOR DUPOUY - ARGENTEUILOverall official - principal investigator
- University of GrenobleOverall official - principal investigator
- HIA SAINTE ANNE - TOULONOverall official - principal investigator
- University of Nice Sophia AntipolisOverall official - principal investigator
- Paris Diderot UniversityOverall official - principal investigator
- CHU BesançonOverall official - principal investigator
- University of LimogesOverall official - principal investigator
- University of BurgundyOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.